Intranasal administration of oxytocin in PWS
- Conditions
- Genetically confirmed diagnosis of Prader-Willi syndrome
- Registration Number
- NL-OMON21542
- Lead Sponsor
- Dutch Growth Research FoundationWestzeedijk 106, 3016 AH RotterdamTel: 010-2251533info@kindengroei.nl
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Other
- Sex
- Not specified
- Target Recruitment
- 28
Inclusion Criteria
Genetically confirmed diagnosis of Prader-Willi syndrome
- Age between 6 and 14 years
- Currently on growth hormone treatment for at least 1 year
- Increased interest in food and/or problems social behavior
Exclusion Criteria
- Severe psychiatric problems
- Non cooperative behaviour - Allergic reactions or hypersensitivity for oxytocin
- Serious illness
- Cardiac abnormalities
- Extremely low dietary intake of less than minimal required intake according to WHO
- Medication to reduce weight (fat)
Study & Design
- Study Type
- Not specified
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To evaluate the effects of intranasal oxytocin administration on appetite, satiety and food intake in children with PWS.
- Secondary Outcome Measures
Name Time Method To evaluate the effects of intranasal oxytocin administration on social behavior in children with PWS.<br>